Menaflex™ collagen meniscus implant (formerly CMI) is a device designed to guide new tissue growth using the body’s own healing process in patients with an irreparable meniscus tear or loss of meniscus tissue. It provides a resorbable scaffold for the growth of new tissue in the meniscus. There are Menaflex devices designed specifically for use in the lateral meniscus and medial meniscus.
Menaflex is cleared for sale in Europe and several other countries around the world. It is not yet available in the United States. Detailed information on knee injuries and conditions, treatment options, and the Menaflex procedure can be found at www.menaflex.com
With the realization that “more meniscus tissue is better” patients and surgeons are looking for ways to save or replace damaged meniscus tissue. The Menaflex™ collagen meniscus implant (formerly CMI) procedure provides a new alternative for treating patients with specific types of meniscus defects.
A successful Menaflex procedure generates new tissue in the meniscus which may delay or prevent development of degenerative joint disease (DJD).
The arthroscopic surgical procedure (medial and lateral) is similar in complexity to meniscus repair or ACL reconstruction. Once a surgeon has attended training on the Menaflex procedure it is possible to start identifying potential candidates and doing surgery immediately.
Standard recovery time for the Menaflex procedure is similar to what is required for a complex meniscus repair or for an ACL reconstruction. A recommended rehabilitation program is available for surgeons and patients.